Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease

A slight decline in cognitive functions and especially in executive functioning after deep brain stimulation (DBS) of the nucleus subthalamicus (STN) in patients with Parkinson's disease (PD) has been described. This study evaluated baseline parameters that contribute to a deterioration of cognitive functioning after DBS. We analyzed data from the neuropsychological protocol in a randomized controlled study comparing DBS with best medical treatment (BMT). Change scores were calculated for the cognitive domains “global cognitive functioning,” “memory,” “working memory,” “attention,” and “executive function.” These domain‐specific change scores were correlated with previously defined preoperative parameters. Compared with the BMT group (63 patients), the STN‐DBS group (60 patients) showed a significant decline only in the domain executive function 6 months after DBS, which was significantly correlated with age, levodopa‐equivalence dosage (LED) and axial subscore of the UPDRS in the off‐medication state at baseline. Multiple regression analysis showed that these three factors explained, however, only about 23% of the variance. Patients with higher age, higher baseline LED, and/or higher axial subscore of the UPDRS at baseline have an increased risk for worsening of executive function after STN‐DBS. High scores of these factors might reflect an advanced stage of disease progression. As these baseline factors explained the variance of the change score executive function only to a minor proportion, other factors including the surgical procedure, the exact placement of the electrode or postsurgical management might be more relevant for a decline in executive functioning after STN‐DBS. © 2010 Movement Disorder Society

[1]  P. S. Achilles THE PSYCHOLOGICAL CORPORATION. , 1923, Science.

[2]  Jacob Cohen Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[3]  F Lhermitte,et al.  Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment , 1989, Neurology.

[4]  Y. Agid,et al.  Does ageing aggravate parkinsonian disability? , 1991, Journal of neurology, neurosurgery, and psychiatry.

[5]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[6]  C. Elger,et al.  Rey Auditory-Verbal Learning Test: structure of a modified German version. , 1997, Journal of clinical psychology.

[7]  M. Yamada,et al.  [Dementia rating scale]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[8]  J. Rothwell,et al.  The impact of deep brain stimulation on executive function in Parkinson's disease. , 2000, Brain : a journal of neurology.

[9]  A L Benabid,et al.  Neuropsychological changes between “off” and “on” STN or GPi stimulation in Parkinson’s disease , 2000, Neurology.

[10]  Marjan Jahanshahi,et al.  What contributes to quality of life in patients with Parkinson's disease? , 2000, Journal of neurology, neurosurgery, and psychiatry.

[11]  J O Rinne,et al.  Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. , 2000, Archives of neurology.

[12]  J. Saint-Cyr,et al.  Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. , 2000, Brain : a journal of neurology.

[13]  A. Benabid,et al.  Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[14]  A. Benabid,et al.  Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  K. Leenders,et al.  Putamen FDOPA uptake and its relationship tot cognitive functioning in PD , 2006, Journal of the Neurological Sciences.

[16]  Paul Krack,et al.  Deep brain stimulation: Neuropsychological and neuropsychiatric issues , 2006, Movement disorders : official journal of the Movement Disorder Society.

[17]  P. Perozzo,et al.  Chronic Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson’s Disease: Effects on Cognition, Mood, Anxiety and Personality Traits , 2006, European Neurology.

[18]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[19]  H M M Smeding,et al.  Pathological Gambling after bilateral STN stimulation in Parkinson disease , 2008 .

[20]  Thomas D Parsons,et al.  Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis , 2006, The Lancet Neurology.

[21]  M. Lanotte,et al.  Apathy and verbal fluency in STN-stimulated PD patients , 2007, Journal of Neurology.

[22]  C. Mariani,et al.  Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  B. Schmand,et al.  Does chronic subthalamic nucleus stimulation in advanced Parkinson’s disease cause invalidating cognitive and behavioural dysfunctions? , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  O. Rascol,et al.  Does ageing influence deep brain stimulation outcomes in Parkinson's disease? , 2007, Movement disorders : official journal of the Movement Disorder Society.

[25]  J. Villemure,et al.  Long‐term cognitive profile and incidence of dementia after STN‐DBS in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[26]  P. Kempster,et al.  Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. , 2007, Brain : a journal of neurology.

[27]  P. Llorca,et al.  Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? , 2007, Neurology.

[28]  T. Babić,et al.  Is quality of life in non‐demented Parkinson’s disease patients related to cognitive performance? A clinic‐based cross‐sectional study , 2008, European journal of neurology.

[29]  Meier,et al.  Leitlinien für Diagnostik und Therapie in der Neurologie: Herausgegeben von der Kommission „Leitlinien“ der Deutschen Gesellschaft für Neurologie (DGN) , 2008 .

[30]  N. Sawamoto,et al.  Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. , 2008, Brain : a journal of neurology.

[31]  Adrian Danek,et al.  Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study , 2008, The Lancet Neurology.

[32]  B. Schmand,et al.  Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  P. A. House,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .